SCHEMBL25804667

SCHEMBL25804667

CCCCc1ccc(-c2noc(CC(C(=O)OC(C)(C)C)P(=O)(OCC)OCC)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 1/20 0.43
S1PR1 P21453 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 2/20 0.41
MAPT P10636 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
S1PR2 O95136 1/20 0.41
S1PR3 Q99500 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
S1PR4 O95977 1/20 0.39
S1PR5 Q9H228 1/20 0.39
SPHK2 Q9NRA0 1/20 0.39
FFAR1 O14842 1/20 0.39
HPGD P15428 2/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23578218 0.97 SPHK1 (0.47) SPHK1S1PR1S1PR2S1PR3LPAR2
SCHEMBL25801780 0.92 SPHK1 (0.43) SPHK1S1PR1NPSR1RAB9AALDH1A1
SCHEMBL23578053 0.91 SPHK1 (0.38) SPHK1S1PR1NPSR1RAB9AALDH1A1
SCHEMBL25804839 0.90 SPHK2 (0.39) SPHK1NPSR1RAB9AALDH1A1SMN1; SMN2
SCHEMBL25801802 0.89 SPHK1 (0.46) SPHK1S1PR1S1PR2S1PR3LPAR2
SCHEMBL23588176 0.89 S1PR4 (0.40) S1PR1NPSR1RAB9AALDH1A1SMN1; SMN2
SCHEMBL23588079 0.89 ACACB (0.46) S1PR1NPSR1RAB9ASMN1; SMN2NPC1
SCHEMBL23588103 0.89 SPHK1 (0.41) SPHK1NPSR1RAB9AALDH1A1SMN1; SMN2
SCHEMBL23578163 0.87 MEN1 (0.33) TP53LMNA
SCHEMBL23588293 0.87 HTT (0.40) RAB9AALDH1A1SMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 SPHK1 3875/4885S1PR1 2590/4885NPSR1 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.